Conference Proceedings

PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine plus nab-paclitaxel (GNP) chemotherapies.

Paul J Ross, Daniel Croagh, Morteza Aghmesheh, Adnan Nagrial, Nguyen Nam, Mehrdad Nikfarjam, Harpreet Singh Wasan, Thankamma V Ajithkumar, Chinenye Iwuji, Alain Hendlisz, Thomas Maher, Anna Kraszewski, Marion Harris

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019

DOI: 10.1200/JCO.2019.37.15_suppl.4125

University of Melbourne Researchers

Grants

Funding Acknowledgements

Nab-paclitaxel was supported by Specialised Therapeutics Australia Pty Ltd.

Citation metrics

2Dimensions

Keywords

Life Sciences & Biomedicine
Science & Technology
Oncology